Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
16M
-
Shares change
-
+3.01M
-
Total reported value, excl. options
-
$393M
-
Value change
-
+$85M
-
Put/Call ratio
-
1.33
-
Number of buys
-
71
-
Number of sells
-
-23
-
Price
-
$24.51
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q2 2020
108 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q2 2020.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16M shares
of 43.4M outstanding shares and own 36.95% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.33M shares), BlackRock Inc. (1.93M shares), Avoro Capital Advisors LLC (1.87M shares), VANGUARD GROUP INC (1.34M shares), STATE STREET CORP (1.03M shares), Slate Path Capital LP (871K shares), Corriente Advisors, LLC (660K shares), Woodline Partners LP (659K shares), GEODE CAPITAL MANAGEMENT, LLC (377K shares), and NORTHERN TRUST CORP (351K shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.